Possible mechanisms by which pro- and prebiotics influence colon carcinogenesis and tumor growth.
Oligofructose and inulin, selective fermentable chicory fructans, have been shown to stimulate the growth of bifidobacteria, which are regarded as beneficial strains in the colon. Studies were designed to evaluate inulin (Raftiline) and oligofructose (Raftilose) for their potential inhibitory properties against the development of colonic aberrant crypt foci (ACF) in rats. ACF are putative preneoplastic lesions from which adenomas and carcinomas may develop in the colon. The results of this study indicate that dietary administration of oligofructose and inulin inhibits the development of ACF in the colon, suggesting the potential colon tumor inhibitory properties of chicory fructans. The degree of ACF inhibition was more pronounced in animals given inulin than in those fed oligofructose. Because these prebiotics selectively stimulate the growth of bifidobacteria, ornithine decarboxylase (ODC) activities, ras-p21 ontoprotein expressions and tumor inhibitory activity of lyophilized cultures of Bifidobacterium longum against chemically induced colon and mammary carcinogenesis and against colonic tumor cell proliferation were examined. Dietary administration of lyophilized cultures of B. longum strongly suppressed colon and mammary tumor development and tumor burden. Inhibition of colon carcinogenesis was associated with a decrease in colonic mucosal cell proliferation and activities of colonic mucosal and tumor ornithine decarboxylase and ras-p21. Human clinical trials are likely to broaden our insight into the importance of the pre- and probiotics in health and disease.
American Health Foundation, Valhalla, NY 10595, USA.
B S
BS
Reddy
D000818:Animals; D001644:Bifidobacterium / Q000187:drug effects* / Q000254:growth & development; D002828:Choristoma / Q000517:prevention & control; D003110:Colonic Neoplasms / Q000517:prevention & control*; D004032:Diet; D005260:Female; D006801:Humans; D007444:Inulin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D015674:Mammary Neoplasms, Animal / Q000517:prevention & control; D009844:Oligosaccharides / Q000008:administration & dosage / Q000627:therapeutic use*; D009955:Ornithine Decarboxylase / Q000378:metabolism; D019936:Probiotics / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats
D009844:Oligosaccharides; C120489:oligofructose; D007444:Inulin; D009955:Ornithine Decarboxylase